AstraZeneca Plc explored a potential acquisition of Bristol Myers Squibb Co., which, if completed, would create one of the world's largest pharmaceutical companies. The two companies held early-stage discussions regarding a combination. News of these talks caused AstraZeneca's shares to plunge as much as 7.8% in early London trading.
The potential megadeal would rank as the largest ever in the pharmaceutical industry and could value the combined entity at approximately $400 billion. It is currently unclear if these discussions are ongoing or if they will ultimately result in a transaction. This proposed merger would unite two major players in the cancer drug market.
Such a deal would face significant regulatory scrutiny, particularly from U.S. antitrust authorities under President Donald Trump's administration. Experts anticipate that the Federal Trade Commission (FTC) would scrutinize the merger due to potential overlaps in drug portfolios and late-stage pipeline assets, likely requiring substantial divestitures. This is especially relevant given Trump's focus on domestic investments and expanding U.S. manufacturing. For instance, in 2019, the Trump FTC required Celgene to sell its psoriasis treatment Otezla for $13.4 billion as part of its acquisition by Bristol Myers.
